Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 20/20 | 1.00 |
| ▸ | ABL1 | P00519 | 17/20 | 1.00 |
| ▸ | HCK | P08631 | 16/20 | 1.00 |
| ▸ | EGFR | P00533 | 16/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 15/20 | 1.00 |
| ▸ | MTOR | P42345 | 15/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 15/20 | 1.00 |
| ▸ | EPHB4 | P54760 | 15/20 | 1.00 |
| ▸ | PRKDC | P78527 | 15/20 | 1.00 |
| ▸ | PI4KB | Q9UBF8 | 15/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 14/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 14/20 | 1.00 |
| ▸ | KDR | P35968 | 14/20 | 0.57 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | EPHA3 | P29320 | 1/20 | 0.53 |
| ▸ | CSK | P41240 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL129868 | 0.85 | PIK3CB (0.73) | SRCABL1HCKEGFRPIK3CB | |
| SCHEMBL18868080 | 0.75 | SRC (0.69) | SRCABL1HCKEGFRPIK3CB | |
| SCHEMBL29388407 | 0.74 | SRC (0.68) | SRCABL1HCKEGFRPIK3CB | |
| SCHEMBL14574612 | 0.74 | SRC (0.68) | SRCABL1HCKEGFRPIK3CB | |
| SCHEMBL3609705 | 0.73 | SRC (1.00) | SRCABL1HCKEGFRPIK3CB | |
| SCHEMBL3613209 | 0.73 | SRC (1.00) | SRCABL1HCKEGFRPIK3CB | |
| SCHEMBL29388399 | 0.72 | SRC (1.00) | SRCABL1HCKEGFRPIK3CB | |
| SCHEMBL20794098 | 0.72 | PIK3CD (0.57) | SRCABL1HCKEGFRPIK3CB | |
| SCHEMBL2464370 | 0.72 | SRC (1.00) | SRCABL1HCKEGFRPIK3CB | |
| SCHEMBL18868085 | 0.72 | SRC (0.72) | SRCABL1HCKEGFRPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230111917-A1 | KINASE ANTAGONISTS | UNIV CALIFORNIA (US) | 2023-04-13 | — | — | US | disclosed |
| EP-2551270-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES FOR USE AS PI3 KINASE ANTAGONISTS | UNIV CALIFORNIA (US) | 2019-06-12 | — | — | EP | disclosed |
| US-8642604-B2 | Substituted pyrazolo[3,2-d]pyrimidines as anti-cancer agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-04 | — | — | US | disclosed |
| EP-2004654-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES FOR USE AS KINASE ANTAGONISTS | UNIV CALIFORNIA (US) | 2013-05-22 | — | — | EP | disclosed |
| US-20110301144-A1 | Kinase Antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-08 | — | — | US | disclosed |
| US-20100009963-A1 | KINASE ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-01-14 | — | — | US | disclosed |
| US-7585868-B2 | Substituted pyrazolo[3,4-D]pyrimidines as kinase antagonists | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-09-08 | — | — | US | disclosed |
| EP-2004654-A2 | KINASE ANTAGONISTS | The Regents of the University of California (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20070293516-A1 | Antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR; 1-isopropyl-3-(3-methoxy-4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-12-20 | — | — | US | disclosed |
| WO-2007114926-A2 | KINASE ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293516-A1 | Antagonists of a lipid kinase such as a PI3 kinase, protein tyrosine kinase, and/or protein serine-threonine kinases such as mTOR; 1-isopropyl-3-(3-methoxy-4-methylphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine | MTOR, PI4KA, PIK3CA | SRC 218/4885ABL1 225/4885HCK 637/4885 |
| US-20230111917-A1 | KINASE ANTAGONISTS | MTOR, RPS6KA3, AKT3 | SRC 131/4885ABL1 137/4885HCK 382/4885 |
| US-20100009963-A1 | KINASE ANTAGONISTS | MTOR, RPS6KA3, AKT3 | SRC 131/4885ABL1 137/4885HCK 382/4885 |
| US-20110301144-A1 | Kinase Antagonists | MTOR, RPS6KA3, AKT3 | SRC 131/4885ABL1 137/4885HCK 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.